Pullman

This research aims to understand the immediate effects of cannabigerol (CBG) on various psychological aspects such as anxiety, stress, mood, memory, impairment, intoxication, and side effects, along with physiological factors including blood pressure, cortisol levels, heart rate variability, electrodermal activity, pain tolerance, and temperature. The study also evaluates potential side effects like sleepiness, dry mouth and eyes, increased appetite, dizziness, and nausea to better grasp the overall impact of CBG on healthy adults. Healthy adults aged 21 and older will be recruited to complete two testing sessions about one week apart. Each participant will receive either a 50 mg oral dose of CBG tincture or a placebo in a randomized, double-blind manner, switching treatments between sessions. Before each session, participants will fast overnight and abstain from cannabis use. During sessions, participants consume a standardized high-fat breakfast, wear a medical-grade wristband for continuous monitoring, provide saliva samples, and complete cognitive and impairment tests. Various assessments occur before and after dosing, including blood pressure readings, anxiety and mood ratings, and a stress-inducing task involving cold water trials and mental arithmetic. Participants will undergo multiple evaluations during each 2.5-hour session, including physiological monitoring of heart rate, electrodermal activity, and blood pressure, as well as psychological ratings of anxiety, stress, mood, and drug effects. Memory tests and pain tolerance assessments are also conducted. Side effects are recorded using rating scales and open-ended questions. After the first session, a one-week washout period precedes the second session, which mirrors the first but with the alternate treatment. The study carefully tracks numerous outcomes to assess how CBG affects both mind and body in this controlled setting.

Researchers are evaluating the effects of hemp-derived cannabinoids on symptoms experienced during menopause and perimenopause in adult women aged 40 to 60. This randomized, double-blind, placebo-controlled study aims to understand the impact of these cannabinoids on psychological and physical symptoms related to menopause, including depression, anxiety, stress, insomnia, and memory issues. The study lasts for a total of three months and includes various cognitive and symptom assessments to capture changes over time. Participants will be randomly assigned to receive either the active hemp-derived cannabinoid product or a placebo. The study includes an initial baseline period of four weeks during which participants complete surveys and cognitive tests twice daily and weekly, respectively, without taking the product. Following baseline, participants enter Phase 1 and Phase 2, each lasting four weeks, where they take the assigned product three times daily and continue twice-daily symptom surveys and weekly cognitive testing, all conducted via smartphone and Zoom sessions. A brief dose escalation occurs during the first week of Phase 1 to help participants adjust. Throughout the study, participants complete monthly assessments of depression, anxiety, and menopause-related symptoms using standardized surveys shortly after Zoom sessions at weeks 1, 5, 9, and 13. They also provide daily reports on emotional and mental symptoms via ecological momentary assessments. Cognitive function is regularly evaluated through a combination of smartphone-based tests and Zoom sessions. The study monitors side effects and adherence closely, and participation concludes after the final Phase 2 assessments and surveys.

Researchers are investigating the effects of hemp-derived minor cannabinoids on symptoms experienced during menopause and perimenopause. This randomized, double-blind, placebo-controlled study will enroll healthy adult women aged 40 to 60 who have psychological and physical symptoms related to menopause or perimenopause. The study aims to understand how these cannabinoids might influence symptoms such as depression, anxiety, stress, insomnia, and memory problems over a 3-month period. Participants will be randomly assigned to receive either an active cannabinoid product or a placebo, both administered as dietary supplements. After an initial Zoom session for consent and cognitive testing, participants will undergo a 4-week baseline period with twice-daily symptom and cognitive assessments via smartphone ecological momentary assessment (EMA). Following baseline, Phase 1 involves taking one dose of the assigned product twice daily for 4 weeks, with ongoing twice-daily surveys and weekly cognitive tests. At the end of Phase 1, participants can choose to double their dose for Phase 2, which lasts another 4 weeks with the same monitoring schedule. Additional Zoom cognitive testing and symptom surveys occur at the end of each phase. Throughout the study, participants will report on emotional and physical symptoms, sleep quality, and any side effects using EMA surveys administered twice daily. Cognitive functions will be evaluated weekly through smartphone tests and during Zoom sessions at key study points. Primary outcomes include monthly assessments of depression, anxiety, and perimenopausal depression using standardized inventories, as well as daily evaluations of emotional and mental symptoms over the full 3 months. The study concludes after Phase 2, totaling approximately 3 months of participation.

Researchers are evaluating the use of ecological momentary assessments through a smartphone app to study behaviors related to tick encounters and tick-borne disease risks across the United States, focusing on the upper Midwest and Northeast, especially Wisconsin. The study aims to understand human behavior in real time and assess the impact of educational messaging on prevention practices like tick checks and bathing or showering. This trial involves up to 1000 participants and builds on prior research showing that educational apps can improve intentions to use tick prevention methods. Participants will use the Tick App to report their daily activities, locations, tick encounters, and prevention behaviors through daily logs. For a portion of the year, the app's opening screen will display prevention messages and reminders, with half of the users receiving an additional reminder about a specific prevention behavior. Users are randomly assigned to groups to compare whether added messages increase prevention actions and reduce tick encounters. Participants are asked to complete at least seven days of daily logs within a year. The study will track changes in the number of tick prevention behaviors over up to 12 months. Researchers will collect data on participant activity and tick encounters, analyze responses to educational messages, and monitor adherence through the app's daily logs. This study helps understand how real-time behavioral data can support tick-bite prevention efforts.

This research aims to explore how eating trout, especially strains developed in Idaho with higher omega-3 fatty acids, may support brain health and mental wellbeing in children and adults. The study seeks to understand consumer preferences for these trout varieties and how nutrition education might increase fish consumption to improve cognitive and emotional health. It addresses a key knowledge gap by testing strategies to encourage fish eating among families, with a focus on sustainability and human health benefits. Participants will be involved in several activities including sensory evaluations of three trout strains by adult and child consumer panels. Children in childcare settings will be divided into control and two treatment groups to test the effects of repeated exposure and child-centered nutrition phrases on eating behaviors and brain health. In the home setting, four treatment groups will explore the impact of nutrition education, fish preparation techniques, repeated exposure, and family meal strategies on fish consumption and cognitive and emotional wellbeing for both children and adults. Throughout the study, researchers will measure changes from baseline to 12 weeks in liking of trout, intake amounts, cognition composite scores, and emotional wellbeing. Sensory preferences will be recorded once upon enrollment. Participants will complete evaluations, receive nutrition education, and engage with puzzles weekly. The study includes children aged 3 to 9 and adults 18 and older, with assessments conducted in childcare and home environments to monitor brain and emotional health outcomes over the 12-week period.